Medifast (MED) Stock Price, News & Analysis

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MED, but not buy additional shares or sell existing shares.
View MED analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued 12 month price targets for Medifast's stock. Their MED share price targets range from $25.00 to $82.00. On average, they predict the company's share price to reach $53.50 in the next twelve months. This suggests a possible upside of 106.3% from the stock's current price.
View analysts price targets for MED or view top-rated stocks among Wall Street analysts.

Medifast's stock was trading at $67.22 at the start of the year. Since then, MED stock has decreased by 61.4% and is now trading at $25.93.
View the best growth stocks for 2024 here.

Medifast saw a increase in short interest in March. As of March 31st, there was short interest totaling 2,660,000 shares, an increase of 29.8% from the March 15th total of 2,050,000 shares. Based on an average trading volume of 384,900 shares, the days-to-cover ratio is presently 6.9 days. Currently, 25.1% of the company's stock are short sold.
View Medifast's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024.
View our MED earnings forecast.

Medifast, Inc. (NYSE:MED) posted its quarterly earnings data on Monday, April, 29th. The specialty retailer reported $0.66 earnings per share for the quarter, missing the consensus estimate of $0.78 by $0.12. The specialty retailer had revenue of $174.74 million for the quarter, compared to the consensus estimate of $168.90 million. Medifast had a trailing twelve-month return on equity of 36.64% and a net margin of 7.55%. The business's revenue for the quarter was down 49.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.67 earnings per share.

Medifast declared a quarterly dividend on Thursday, September 7th. Shareholders of record on Tuesday, September 19th will be paid a dividend of $1.65 per share on Tuesday, November 7th. This represents a $6.60 dividend on an annualized basis and a yield of 25.45%. The ex-dividend date is Monday, September 18th.
Read our dividend analysis for MED.

Medifast (NYSE:MED) pays an annual dividend of $6.60 per share and currently has a dividend yield of 0.00%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 106.45%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on EPS estimates, MED will have a dividend payout ratio of 210.86% in the coming year. This indicates that the company may not be able to sustain their current dividend.
Read our dividend analysis for MED.

ETFs with the largest weight of Medifast (NYSE:MED) stock in their portfolio include Invesco S&P SmallCap High Dividend Low Volatility ETF (XSHD), Invesco S&P SmallCap Consumer Staples ETF (PSCC) and Global X Health & Wellness ETF (BFIT).

Medifast updated its second quarter 2024 earnings guidance on Monday, April, 29th. The company provided EPS guidance of 0.050-0.400 for the period, compared to the consensus EPS estimate of 0.780. The company issued revenue guidance of $150.0 million-$170.0 million, compared to the consensus revenue estimate of $168.9 million.

44 employees have rated Medifast Chief Executive Officer Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among the company's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Home Depot (HD), Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM).

Medifast's stock is owned by many different retail and institutional investors. Top institutional shareholders include Principal Financial Group Inc. (0.59%), Allspring Global Investments Holdings LLC (0.39%), Denali Advisors LLC (0.24%), Chickasaw Capital Management LLC (0.17%), BNP Paribas Financial Markets (0.13%) and DGS Capital Management LLC (0.10%). Insiders that own company stock include Andrea B Thomas, Constance J Hallquist, Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Jeffrey J Brown, Kevin G Byrnes and Scott Schlackman.
View institutional ownership trends.

Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.